Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 0123 and Sacituzumab Govitecan in Advanced Breast Cancer
NCT06612203Phase 2Active, not recruiting
- Sponsor
- MEDSIR
- Start
- Jan 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of zedoresertib in breast cancer, sponsored by MEDSIR. Primary endpoints: Recommended Phase II Dose at 42 days and Objective Response Rate at 9 months. Started Jan 2025; status: active, not recruiting.
02
Drugs
zedoresertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06612203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06612203.